Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,894 across all filing types
Latest filing 2019-10-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于控股子公司天士力生物医药股份有限公司首次公开发行股份并在香港联交所主板上市的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a subsidiary's initial public offering (IPO) and listing on the Hong Kong Stock Exchange. It includes details about the listing hearing, regulatory review, and the need for further approvals. The document is short (582 characters) and serves as a progress update rather than a full financial report or detailed filing. It does not contain financial statements or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPO progress.
2019-10-28 Chinese
天士力关于公司2019年三季度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement of the company's main operating data for the third quarter of 2019. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment field, product, and region for the period January to September 2019 compared to the same period in 2018. The document is 3348 characters long, which is relatively short but contains substantive financial data and analysis for a period shorter than a full fiscal year (nine months). It is not a full annual report but an interim/quarterly report covering the third quarter results. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2019
2019-10-28 Chinese
2019年第三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "2019 年第三季度报告" which translates to "2019 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2019. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements and management explanations of financial changes, which are typical of an Interim / Quarterly Report. There is no indication that this is an annual report, audit report, or earnings release summary. The detailed financial data and period coverage confirm it is an Interim / Quarterly Report (IR). 9M 2019
2019-10-28 Chinese
关于全资子公司药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary's drug passing a generic drug consistency evaluation by the National Medical Products Administration. It details the drug's background, regulatory approval, market information, and potential impact on the company. The document is short (1178 characters) and serves as a regulatory announcement about a product approval and its implications rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and company impact, which does not fit other specific categories like earnings, management changes, or capital updates.
2019-10-22 Chinese
关于子公司天士力生物医药股份有限公司首次公开发行境外上市外资股（H股）获得中国证监会批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval from the China Securities Regulatory Commission (CSRC) for a subsidiary's initial public offering (IPO) of overseas listed foreign shares (H shares). It details the approval for the issuance and the conditions for listing on the Hong Kong Stock Exchange. The document is short (599 characters) and serves as a formal announcement of regulatory approval for a capital raising event. This fits the category of Capital/Financing Update (CAP), as it relates to fundraising and capital structure changes. It is not a full financial report or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2019-10-21 Chinese
独立董事对第一期员工持股计划展期事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the extension of the first employee stock ownership plan. It references relevant laws and regulations and confirms compliance and approval of the extension. This is a governance-related document concerning board-level decisions and compliance with regulatory requirements. It is not a full annual report, audit report, earnings release, or other financial report. It is also not a simple announcement of a report publication. The content fits best under Board/Management Information (MANG) as it relates to board decisions and management governance matters.
2019-10-16 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.